According to the above results, we suggest that the mechanism of Lomitapide’s inhibiting pancreatic cancer cell is through inhibiting both SSTR5 and palmitic acid binding to ZDHHC5. This evidence concerns the gene ZDHHC5 and familial pancreatic carcinoma.